DENVER, March 23, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that effective as of market open today, March 23, 2021, its common shares and warrants…

Source

Previous articleCOMPASS Pathways granted two US patents
Next articleMindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform (“Cope”); Cope Expected to Be World’s First in Vivo Psychedelic Benchmark Data Set